ERAS
Erasca, Inc.
Overview
Erasca, Inc is a Healthcare company operating in Biotechnology with a $4.69B market cap.
ERAS missed consensus EPS by 1.0% in Q1 FY2026, reported May 6, 2026.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q1 FY20262026-05-06EPS$-0.60 vs $-0.11-100.0%Rev$0 vs ——EODHD
- Q4 FY20252026-03-18EPS$-0.10 vs $-0.11+8.3%Rev$0 vs ——EODHD
- Q3 FY20252025-11-11EPS$-0.11 vs $-0.10-5.8%Rev$0 vs ——EODHD
- Q2 FY20252025-08-11EPS$-0.12 vs $-0.120.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-12EPS$-0.11 vs $-0.13+15.4%Rev$0 vs ——EODHD
- Q4 FY20242025-03-19EPS$-0.11 vs $-0.13+15.4%Rev$4.2M vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.11 vs $-0.17+35.3%Rev$0 vs ——EODHD
- Q2 FY20242024-08-11EPS$-0.29 vs $-0.18-61.1%Rev$0 vs ——EODHD
- Q1 FY20242024-05-07EPS$-0.23 vs $-0.20-15.0%Rev$0 vs ——EODHD
- Q4 FY20232024-03-26EPS$-0.20 vs $-0.23+13.0%Rev$5.6M vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.20 vs $-0.22+9.1%Rev$0 vs ——EODHD
- Q2 FY20232023-08-09EPS$-0.21 vs $-0.24+12.5%Rev$0 vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.22 vs $-0.31+29.0%Rev$0 vs ——EODHD
- Q4 FY20222023-03-22EPS$-1.06 vs $-0.32-100.0%Rev$0 vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.29 vs $-0.31+6.5%Rev$0 vs ——EODHD
- Q2 FY20222022-08-10EPS$-0.30 vs $-0.33+9.1%Rev$0 vs ——EODHD
- Q1 FY20222022-05-11EPS$-0.31 vs $-0.29-6.9%Rev$0 vs ——EODHD
- Q4 FY20212022-03-23EPS$-0.26 vs $-0.34+23.5%Rev$0 vs ——EODHD
- Q3 FY20212021-11-09EPS$-0.46 vs $-0.32-43.8%Rev$0 vs ——EODHD
- Q2 FY20212021-08-25EPS$-1.20 vs $-0.65-84.6%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-06 | $-0.60 | $-0.11 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $-0.10 | $-0.11 | +8.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.11 | $-0.10 | -5.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.12 | $-0.12 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.11 | $-0.13 | +15.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-0.11 | $-0.13 | +15.4% | $4.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.11 | $-0.17 | +35.3% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.29 | $-0.18 | -61.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.23 | $-0.20 | -15.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-26 | $-0.20 | $-0.23 | +13.0% | $5.6M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.20 | $-0.22 | +9.1% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.21 | $-0.24 | +12.5% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.22 | $-0.31 | +29.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-1.06 | $-0.32 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.29 | $-0.31 | +6.5% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.30 | $-0.33 | +9.1% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.31 | $-0.29 | -6.9% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-0.26 | $-0.34 | +23.5% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.46 | $-0.32 | -43.8% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-25 | $-1.20 | $-0.65 | -84.6% | $0 | — | — | EODHD |
Source: EODHD. ERAS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ERAS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2023 | $1.76 | $1.26 | +40.0% | -4.6% | -4.5% |
| Q4 FY2023 | $1.63 | $1.23 | +32.6% | -4.6% | -5.4% |
| Q3 FY2023 | $1.94 | $1.49 | +30.1% | +4.5% | +2.9% |
| Q2 FY2023 | $2.00 | $1.46 | +37.3% | -0.4% | +0.1% |
| Q1 FY2022 | $2.16 | $1.57 | +37.6% | +0.6% | +1.0% |
| Q4 FY2022 | $1.84 | $1.40 | +31.1% | +3.2% | +3.8% |
| Q3 FY2022 | $2.16 | $1.57 | +37.7% | -3.4% | -6.2% |
| Q2 FY2022 | $2.26 | $1.58 | +43.1% | +2.8% | +4.8% |
| Q1 FY2021 | $2.05 | $1.56 | +31.5% | +0.1% | +0.6% |
| Q4 FY2021 | $1.88 | $1.43 | +31.2% | -1.1% | -1.9% |
Guidance change history
Sample- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
- Q1 FY2022Raised2022-04-15
- Q4 FY2022Raised2022-13-15
- Q3 FY2022Raised2022-10-15
- Q2 FY2022Raised2022-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Jonathan E LimCEO2 yr1 callCurrentSample
CEO since 2024 • 1/2 beats (50%) • guidance suspended Q3 FY2023
- David M ChackoCFO2 yr1 callCurrentSample
CFO since 2024 • 1/2 beats (50%) • last call held guidance Q3 FY2023
- Ebun GarnerChief Legal Officer2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2023
- Shannon MorrisChief Medical Officer2 yr1 callCurrentSample
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last guidance cut Q3 FY2023
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ERAS.
$ curl https://api.spokenalpha.com/v1/companies/ERASFAQ
Frequently asked about ERAS
Where can I find Erasca, Inc.'s (ERAS) earnings call transcripts?
Spoken Alpha indexes ERAS's earnings call transcripts at https://spokenalpha.com/companies/ERAS. Each call links to attributed speakers and parsed analyst Q&A. Erasca, Inc.'s own investor relations page is at https://investors.erasca.com/.
When was Erasca, Inc.'s most recent earnings call?
Erasca, Inc. (ERAS) held its most recent earnings call on 2024-03-29, covering fiscal Q4 2023.
What sector is ERAS in?
Erasca, Inc. (ERAS) operates in the Healthcare sector (Biotechnology industry).